These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 30134579)

  • 1. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
    Miranda O; Farooqui M; Siegfried JM
    Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
    Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
    Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis.
    Liang H; Wang M
    Onco Targets Ther; 2020; 13():2491-2510. PubMed ID: 32273721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer.
    Sylvester PW
    Clin Transl Med; 2014 Dec; 3(1):30. PubMed ID: 26932375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
    Moosavi F; Giovannetti E; Saso L; Firuzi O
    Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment.
    Rothenberger NJ; Stabile LP
    Cancers (Basel); 2017 Apr; 9(4):. PubMed ID: 28441771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the hepatocyte growth factor-cMET axis in cancer therapy.
    Blumenschein GR; Mills GB; Gonzalez-Angulo AM
    J Clin Oncol; 2012 Sep; 30(26):3287-96. PubMed ID: 22869872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Met expression in renal cell carcinoma with bone metastases.
    Silva Paiva R; Gomes I; Casimiro S; Fernandes I; Costa L
    J Bone Oncol; 2020 Dec; 25():100315. PubMed ID: 33024658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated HGF-c-Met Axis in Head and Neck Cancer.
    Arnold L; Enders J; Thomas SM
    Cancers (Basel); 2017 Dec; 9(12):. PubMed ID: 29231907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
    Sattler M; Reddy MM; Hasina R; Gangadhar T; Salgia R
    Ther Adv Med Oncol; 2011 Jul; 3(4):171-84. PubMed ID: 21904579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-MET as a potential therapeutic target and biomarker in cancer.
    Sierra JR; Tsao MS
    Ther Adv Med Oncol; 2011 Nov; 3(1 Suppl):S21-35. PubMed ID: 22128285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c-Met-Mediated Epithelial-to-Mesenchymal Transition.
    Hsieh YS; Liao CH; Chen WS; Pai JT; Weng MS
    J Cell Biochem; 2017 Dec; 118(12):4639-4651. PubMed ID: 28485480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.
    Della Corte CM; Fasano M; Papaccio F; Ciardiello F; Morgillo F
    Biomedicines; 2014 Nov; 2(4):345-358. PubMed ID: 28548075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
    Yap TA; Sandhu SK; Alam SM; de Bono JS
    Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the hepatocyte growth factor/scatter factor receptor tyrosine kinase is localized to epithelia in the adult mouse.
    Yang XM; Park M
    Lab Invest; 1995 Oct; 73(4):483-91. PubMed ID: 7474919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promise and challenges on the horizon of MET-targeted cancer therapeutics.
    Zhang YW
    World J Biol Chem; 2015 May; 6(2):16-27. PubMed ID: 26009700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications.
    Zorzetto M; Ferrari S; Saracino L; Inghilleri S; Stella GM
    Transl Lung Cancer Res; 2012 Sep; 1(3):194-207. PubMed ID: 25806181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.